Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A
Rattachement africain : kg, ru. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background/Objectives: Overcoming resistance to diuretics is extremely important in decompensated chronic heart failure (HF). The objective of this study was to assess the efficacy and safety of oral acetazolamide, in addition to standard therapy, in HF patients admitted to the hospital with decompensation requiring intravenous loop diuretic therapy. Methods: In this open-label, prospective, multicenter, randomized trial, we included 416 patients hospitalized with decompensated HF. The patients were randomized into two groups: (1) standard therapy, and (2) standard therapy + acetazolamide orally 250 mg 3 times a day in the first 3 days of hospitalization. At randomization, oral thiazide/thiazide-like and loop diuretics were stopped, and intravenous furosemide was initiated. Results: Successful decongestion within 72 h of randomization was observed in 82 patients (39.6%) in the acetazolamide group and in 83 patients (39.7%) in the standard therapy group (p = 0.983). There was a significant difference in the increase in diuresis in the first 72 h (p = 0.028) and in natriuresis on the 2nd day (p = 0.04). There were no differences between the groups in duration of stay in the intensive care unit, duration of index hospitalization, 6 min walk test distance, and clinical assessment scale scores. Death from any cause occurred in three (1.4%) patients in the acetazolamide group, and in the same number of patients in the standard therapy group (p = 0.996). Death from cardiovascular cause and due to decompensated HF also did not differ between the groups during follow-up. Conclusions: The addition of acetazolamide to standard therapy in decompensated chronic HF resulted in a higher cumulative urine output during the first 72 h and natriuresis on the 2nd day after randomization.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Acetazolamide per os in Decompensated Chronic Heart Failure: Randomized Multicenter Trial ORION-A
- Date Crossref
- 16/09/2025
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Kyrgyz-Russian Slavic University named after B.N. Yeltsin pays non établi dans la noticeUniversité ou école supérieure
-
Samara State Medical University Department of Hospital Therapy with Courses in Hematology and Transfusiology pays non établi dans la noticeUniversité ou école supérieure
-
Federal Almazov North-West Medical Research Centre pays non établi dans la noticeStructure de recherche
-
Altai State Medical University Department of Cardiology and Cardiovascular Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Volgograd Regional Clinical Oncology Center pays non établi dans la noticeÉtablissement de santé
-
Saratov State Medical University Department of Hospital Therapy pays non établi dans la noticeUniversité ou école supérieure
-
Ulyanovsk State University Department of Therapy and Occupational Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Privolzhsky Research Medical University Department of Endocrinology and Internal Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Irkutsk State Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Kazan State Medical University Department of Propaedeutics of Internal Diseases Named After Professor S.S. Zimnitsky pays non établi dans la noticeUniversité ou école supérieure
-
Ryazan State Medical University named after Academician I.P. Pavlov Department of Hospital Therapy with a Course of Medical and Social Expertise pays non établi dans la noticeUniversité ou école supérieure
-
Interstate Educational Organization of Higher Education Kyrgyz-Russian Slavic University Named After the First President of the Russian Federation B.N. Yeltsin Department of Therapy №2 pays non établi dans la noticeUniversité ou école supérieure
Kyrgyz-Russian Slavic University named after B.N. Yeltsin, Department of Hospital Therapy with Courses in Hematology and Transfusiology — Samara State Medical University et Federal Almazov North-West Medical Research Centre, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.